ANB033 / AnaptysBio - LARVOL DELTA

ANB033 (CD122 antagonist) (GlobeNewswire) - "(i) Phase 1b cohort in celiac initiated - Top-line Phase 1b data anticipated in Q4 2026; (ii) Plan to initiate an additional Phase 1b trial in a second inflammatory disease in 2026 - Exploring eosinophilic esophagitis as a potential indication."

New P1 trial • P1 data • Trial status • Celiac Disease • Eosinophilic Esophagitis

Biopharma Co Profile (GlobeNewswire) - "AnaptysBio...announced today that its Board of Directors approved plans to explore separating its business into two independent, publicly traded companies, each poised for strong, sustainable growth.....Upon completion, Biopharma Co will be a clinical-stage biotechnology company focused on the development and potential commercialization of innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033 and ANB101."

Commercial • Immunology • Inflammation

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14 (GlobeNewswire) - "The event will cover: (i) ANB033’s mechanism of action, an antagonist of the CD122 receptor; (ii) Preclinical data and initial Phase 1a data in healthy volunteers; (iii) Celiac disease (CeD) disease biology and Phase 1b trial design."

Clinical protocol • P1 data • Preclinical • Celiac Disease

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) - "PORTFOLIO UPDATES:...ANB033 (CD122 antagonist): (i) Phase 1 trial ongoing in healthy volunteers; (ii) Plan to initiate Phase 1b cohort for ANB033 in initial indication, celiac disease, by Q4 2025; (iii) Additional information to be disclosed at ANB033-focused R&D event in Q4 2025."

Clinical • New P1 trial • Trial status • Celiac Disease

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) - "ANB033 (CD122 antagonist): Enrollment ongoing for Phase 1a trial in healthy volunteers. Phase 1b indication to be disclosed at a 2025 R&D event. ANB101 (BDCA2 modulator): Phase 1a trial to initiate in healthy volunteers in Q1 2025....Research and development expenses were $42.6 million and $163.8 million for the three and twelve months ended December 31, 2024, compared to $33.5 million and $132.3 million for the three and twelve months ended December 31, 2023. The increase was due primarily to development costs for rosnilimab, ANB032, ANB033 and ANB101 offset by a decrease in development costs for imsidolimab."

Commercial • New P1 trial • Trial status • Immunology

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Updates on Wholly Owned ICM Pipeline:...(i) ANB033 (anti-CD122 antagonist antibody): IND application accepted by FDA in July 2024; Phase 1 trial initiation in healthy volunteers anticipated in Q4 2024; (ii) ANB101 (BDCA2 modulator antibody): Plan to submit IND application in Q4 2024."

IND • New P1 trial • Inflammation